Ongoing Clinical Trials with Monoclonal Antibodies in Schizophrenia
BACKGROUND: In recent years, there have been advances in the comprehension of the aetiology of schizophrenia, relating immune dysregulation as causal factor. Lifelong cytokine concentrations alterations are detected, which depend on the timing or severity of the disease. Several anti-inflammatory dr...
| Autor principal: | |
|---|---|
| Formato: | masterThesis |
| Idioma: | eng |
| Publicado em: |
2020
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/128723 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/128723 |